Trials (The Prof. Dr. Ion Chiricuta Institute of Oncology: Revision history

15 December 2025

• curprev 13:3813:38, 15 December 2025‎ Francine talk contribs‎ 91,107 bytes +185‎ No edit summary undo

6 December 2025

• curprev 12:4212:42, 6 December 2025‎ Lucas talk contribs‎ m 90,922 bytes +1,701‎ Update categories. undo

4 December 2025

• curprev 15:3215:32, 4 December 2025‎ Larysse talk contribs‎ 89,221 bytes +49‎ No edit summary undo

2 December 2025

• curprev 14:0114:01, 2 December 2025‎ Lucas talk contribs‎ m 89,172 bytes +90‎ Update categories. undo

28 October 2024

• curprev 17:2317:23, 28 October 2024‎ Victor talk contribs‎ 89,082 bytes −6‎ No edit summary undo
• curprev 17:1717:17, 28 October 2024‎ Victor talk contribs‎ m 89,088 bytes 0‎ Victor moved page Trials (The "Prof. Dr. Ion Chiricuta" Institute of Oncology to Trials (The Prof. Dr. Ion Chiricuta Institute of Oncology undo
• curprev 17:1617:16, 28 October 2024‎ Victor talk contribs‎ m 89,088 bytes 0‎ Victor moved page Trials (The “Prof. Dr. Ion Chiricuta” Institute of Oncology to Trials (The "Prof. Dr. Ion Chiricuta" Institute of Oncology undo

5 December 2023

• curprev 14:2814:28, 5 December 2023‎ Francine talk contribs‎ 89,088 bytes +89,088‎ Created page with "{{forpatients}} {{forresearchers}} {{forproviders}} Go back to The “Prof. Dr. Ion Chiricuta” Institute of Oncology page '''NCTID''': NCT06112314 '''Title''': IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) '''Study Summary''': This is a phase 3, randomized, controlled study of IMC-F106C plus nivolumab compared to standard nivolumab regimens in HLA-A*02:01-positive participants with previously untreated ad..."